Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
157.70
-2.11 (-1.32%)
At close: Aug 13, 2025, 4:00 PM
158.00
+0.30 (0.19%)
After-hours: Aug 13, 2025, 7:45 PM EDT
Natera Revenue
Natera had revenue of $546.60M in the quarter ending June 30, 2025, with 32.24% growth. This brings the company's revenue in the last twelve months to $1.96B, up 44.38% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$1.96B
Revenue Growth
+44.38%
P/S Ratio
10.57
Revenue / Employee
$442,997
Employees
4,434
Market Cap
21.64B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NTRA News
- 5 days ago - Natera shares surge 17% after strong Q2 results and upgraded guidance - Invezz
- 6 days ago - Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Natera Reports Second Quarter 2025 Financial Results - Business Wire
- 6 days ago - Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions - Business Wire
- 12 days ago - Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations - Business Wire
- 13 days ago - Natera to Report Its Second Quarter Results on August 7, 2025 - Business Wire
- 15 days ago - Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer - Business Wire
- 20 days ago - PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT - Business Wire